{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T20:27:43Z","timestamp":1786739263493,"version":"build-2736575974"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n                  <jats:p>Persistent avascular retina (PAR) refers to retinal areas where vascular development permanently arrests in premature children. In the last decade, the first-line treatment for retinopathy of prematurity (ROP) has shifted from laser photocoagulation to antivascular endothelial growth factor (VEGF) therapy, leading to the increased observation of PAR in eyes treated for ROP. Emerging evidence suggests that PAR could pose a risk for late reactivation of ROP, retinal breaks, or detachment. Consequently, PAR has emerged as an important finding in eyes of regressed ROP. In this review, we summarize the recent understanding of PAR, including its pathophysiologic mechanism, prevalence, clinical pathological significance, and management. We conclude that PAR can be often observed in eyes treated with anti-VEGF therapy (type 1 ROP) and in those that regress without treatment (type 2 ROP). Current management of PAR lacks consensus; however, since PAR can potentially cause late reactivation or rhegmatogenous retinal detachment after achieving regression of ROP, treatment with laser photocoagulation should be considered, and lifelong monitoring is recommended.<\/jats:p>","DOI":"10.4103\/tjo.tjo-d-24-00157","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T11:00:22Z","timestamp":1752836422000},"page":"267-271","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Persistent avascular retina in eyes with retinopathy of prematurity: A comprehensive review"],"prefix":"10.4103","volume":"16","author":[{"given":"Tomoya","family":"Murakami","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Shiley Eye Institute, University of California San Diego, San Diego, California"},{"name":"Department of Ophthalmology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Nudleman","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Shiley Eye Institute, University of California San Diego, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,7,18]]},"reference":[{"key":"R1-20260629","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.earlhumdev.2007.11.009","article-title":"Retinopathy of prematurity: A global perspective of the epidemics, population of babies at risk and implications for control","volume":"84","author":"Gilbert","year":"2008","journal-title":"Early Hum Dev"},{"key":"R2-20260629","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/j.ophtha.2021.05.031","article-title":"International classification of retinopathy of prematurity, third edition","volume":"128","author":"Chiang","year":"2021","journal-title":"Ophthalmology"},{"key":"R3-20260629","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.ophtha.2014.05.015","article-title":"Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: Report on fluorescein angiographic findings","volume":"121","author":"Lepore","year":"2014","journal-title":"Ophthalmology"},{"key":"R4-20260629","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ophtha.2017.08.005","article-title":"Follow-up to age 4 years of treatment of type 1 retinopathy of prematurity intravitreal bevacizumab injection versus laser: Fluorescein angiographic findings","volume":"125","author":"Lepore","year":"2018","journal-title":"Ophthalmology"},{"key":"R5-20260629","doi-asserted-by":"crossref","first-page":"101018","DOI":"10.1016\/j.preteyeres.2021.101018","article-title":"Assessment and management of retinopathy of prematurity in the era of anti-vascular endothelial growth factor (VEGF)","volume":"88","author":"Tsai","year":"2022","journal-title":"Prog Retin Eye Res"},{"key":"R6-20260629","doi-asserted-by":"crossref","first-page":"125","DOI":"10.4103\/joco.joco_38_23","article-title":"An update on anti-vascular endothelial growth factor treatment for retinopathy of prematurity","volume":"35","author":"Nowroozzadeh","year":"2023","journal-title":"J Curr Ophthalmol"},{"key":"R7-20260629","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/ICU.0000000000000787","article-title":"Adult retinopathy of prematurity: Treatment implications, long term sequelae, and management","volume":"32","author":"Chang","year":"2021","journal-title":"Curr Opin Ophthalmol"},{"key":"R8-20260629","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1146\/annurev-vision-093022-021420","article-title":"Pathophysiology of retinopathy of prematurity","volume":"9","author":"Hartnett","year":"2023","journal-title":"Annu Rev Vis Sci"},{"key":"R9-20260629","doi-asserted-by":"crossref","first-page":"7822","DOI":"10.1158\/0008-5472.CAN-04-0934","article-title":"VEGF165b, an inhibitory vascular endothelial growth factor splice variant: Mechanism of action, in vivo effect on angiogenesis and endogenous protein expression","volume":"64","author":"Woolard","year":"2004","journal-title":"Cancer Res"},{"key":"R10-20260629","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1136\/bjophthalmol-2013-304109","article-title":"Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone II retinopathy of prematurity","volume":"98","author":"Tahija","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"R11-20260629","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ajo.2018.09.039","article-title":"A spectrum of regression following intravitreal bevacizumab in retinopathy of prematurity","volume":"198","author":"Chen","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"R12-20260629","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jcjo.2020.05.017","article-title":"Fluorescein angiographic features post-intravitreal bevacizumab for retinopathy of prematurity: Can they support rescue laser photocoagulation to the avascular retina","volume":"55","author":"Gonzalez","year":"2020","journal-title":"Can J Ophthalmol"},{"key":"R13-20260629","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1007\/s10792-021-02119-y","article-title":"Angiographic findings in cases with a history of severe retinopathy of prematurity treated with anti-VEGFs: Follow-up to age 6 years","volume":"42","author":"Celiker","year":"2022","journal-title":"Int Ophthalmol"},{"key":"R14-20260629","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s40942-022-00402-3","article-title":"Long-term peripheral retinal vascular behavior in retinopathy of prematurity patients treated with ranibizumab intravitreal injection as monotherapy using fluorescein angiography","volume":"8","author":"Al Rasheed","year":"2022","journal-title":"Int J Retina Vitreous"},{"key":"R15-20260629","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.oret.2019.01.016","article-title":"Fluorescein angiography in retinopathy of prematurity: Comparison of infants treated with bevacizumab to those with spontaneous regression","volume":"3","author":"Mansukhani","year":"2019","journal-title":"Ophthalmol Retina"},{"key":"R16-20260629","doi-asserted-by":"crossref","first-page":"100281","DOI":"10.1016\/j.xops.2023.100281","article-title":"Persistent vascular anomalies in retinopathy of prematurity children: Ultrawide-field fluorescein angiography findings until school age","volume":"3","author":"Ling","year":"2023","journal-title":"Ophthalmol Sci"},{"key":"R17-20260629","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jaapos.2011.12.157","article-title":"Fluorescein angiography to estimate normal peripheral retinal nonperfusion in children","volume":"16","author":"Blair","year":"2012","journal-title":"J AAPOS"},{"key":"R18-20260629","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ophtha.2023.09.032","article-title":"Imaging features associated with persistent avascular retina in retinopathy of prematurity","volume":"131","author":"Robles-Holmes","year":"2024","journal-title":"Ophthalmology"},{"key":"R19-20260629","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3928\/23258160-20160229-12","article-title":"Very late reactivation of retinopathy of prematurity after monotherapy with intravitreal bevacizumab","volume":"47","author":"Snyder","year":"2016","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"R20-20260629","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3928\/23258160-20170301-10","article-title":"Reactivation of retinopathy of prematurity three years after treatment with bevacizumab","volume":"48","author":"Hajrasouliha","year":"2017","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"R21-20260629","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jaapos.2023.05.008","article-title":"Reactivation of retinopathy of prematurity six years after intravitreal injection of bevacizumab","volume":"27","author":"Yasin","year":"2023","journal-title":"J AAPOS"},{"key":"R22-20260629","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jaapos.2021.02.004","article-title":"Very late-onset reactivation of retinopathy of prematurity post anti-VEGF bevacizumab treatment for type 1 ROP: A case report","volume":"25","author":"Taylor","year":"2021","journal-title":"J AAPOS"},{"key":"R23-20260629","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3928\/23258160-20180803-11","article-title":"Late ROP reactivation and retinal detachment in a teenager","volume":"49","author":"Golas","year":"2018","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"R24-20260629","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.oret.2020.02.001","article-title":"Reactivation of retinopathy of prematurity in adults and adolescents","volume":"4","author":"Uner","year":"2020","journal-title":"Ophthalmol Retina"},{"key":"R25-20260629","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1007\/s00417-021-05137-9","article-title":"Comparison of 5-year safety and efficacy of laser photocoagulation and intravitreal bevacizumab injection in retinopathy of prematurity","volume":"259","author":"Murakami","year":"2021","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R26-20260629","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.oret.2019.12.015","article-title":"Late-onset retinal findings and complications in untreated retinopathy of prematurity","volume":"4","author":"Hamad","year":"2020","journal-title":"Ophthalmol Retina"},{"key":"R27-20260629","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/S0161-6420(01)00660-1","article-title":"Adult retinopathy of prematurity: Outcomes of rhegmatogenous retinal detachments and retinal tears","volume":"108","author":"Kaiser","year":"2001","journal-title":"Ophthalmology"},{"key":"R28-20260629","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/00006982-200406000-00006","article-title":"Retinal detachment of regressed retinopathy of prematurity in children aged 2 to 15 years","volume":"24","author":"Park","year":"2004","journal-title":"Retina"},{"key":"R29-20260629","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ajo.2020.08.027","article-title":"Reoperation rates of patients undergoing primary noncomplex retinal detachment surgery in a cohort of the IRIS registry","volume":"222","author":"Rao","year":"2021","journal-title":"Am J Ophthalmol"},{"key":"R30-20260629","doi-asserted-by":"crossref","first-page":"88.e1","DOI":"10.1016\/j.jaapos.2018.10.013","article-title":"Refractive outcomes comparing primary laser to primary bevacizumab with delayed laser for type 1 ROP","volume":"23","author":"Anand","year":"2019","journal-title":"J AAPOS"}],"container-title":["Taiwan Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/tjo.TJO-D-24-00157","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:27:21Z","timestamp":1786735641000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/tjo.TJO-D-24-00157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,18]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/tjo.tjo-d-24-00157","relation":{},"ISSN":["2211-5056","2211-5072"],"issn-type":[{"value":"2211-5056","type":"print"},{"value":"2211-5072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,18]]},"assertion":[{"value":"2024-12-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-18","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}